Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study

Merkel cell carcinoma (MCC) is a rare aggressive form of skin cancer originating in neuroendocrine cells. The antiprogrammed death ligand 1 (PD-L1) monoclonal antibody (mAb) avelumab has been approved for treatment of MCC, but options are limited, should it be ineffective as a monotherapy. Combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Drusbosky, Leylah, Nangia, Chaitali, Nguyen, Andrew, Szeto, Christopher, Newton, Yulia, Spilman, Patricia, Reddy, Sandeep Bobby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484858/
https://www.ncbi.nlm.nih.gov/pubmed/32913030
http://dx.doi.org/10.1136/jitc-2020-001098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484858/
https://www.ncbi.nlm.nih.gov/pubmed/32913030
http://dx.doi.org/10.1136/jitc-2020-001098

Ejemplares similares